- Home
- IFRX vs FCNCP Comparison
IFRX vs FCNCP Comparison
Compare IFRX & FCNCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- FCNCP
- Stock Information
- Founded
- IFRX 2007
- FCNCP N/A
- Country
- IFRX Germany
- FCNCP United States
- Employees
- IFRX N/A
- FCNCP 17475
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- FCNCP Major Banks
- Sector
- IFRX Health Care
- FCNCP Finance
- Exchange
- IFRX Nasdaq
- FCNCP Nasdaq
- Market Cap
- IFRX 53.5M
- FCNCP N/A
- IPO Year
- IFRX 2017
- FCNCP N/A
- Fundamental
- Price
- IFRX $1.15
- FCNCP $21.79
- Analyst Decision
- IFRX Strong Buy
- FCNCP
- Analyst Count
- IFRX 5
- FCNCP 0
- Target Price
- IFRX $7.40
- FCNCP N/A
- AVG Volume (30 Days)
- IFRX 977.4K
- FCNCP N/A
- Earning Date
- IFRX 11-07-2025
- FCNCP N/A
- Dividend Yield
- IFRX N/A
- FCNCP N/A
- EPS Growth
- IFRX N/A
- FCNCP N/A
- EPS
- IFRX N/A
- FCNCP N/A
- Revenue
- IFRX $191,224.00
- FCNCP N/A
- Revenue This Year
- IFRX N/A
- FCNCP N/A
- Revenue Next Year
- IFRX $1,216.24
- FCNCP N/A
- P/E Ratio
- IFRX N/A
- FCNCP N/A
- Revenue Growth
- IFRX 54.36
- FCNCP N/A
- 52 Week Low
- IFRX $0.71
- FCNCP N/A
- 52 Week High
- IFRX $2.82
- FCNCP N/A
- Technical
- Relative Strength Index (RSI)
- IFRX 45.61
- FCNCP 49.26
- Support Level
- IFRX $1.45
- FCNCP $21.56
- Resistance Level
- IFRX $1.77
- FCNCP $21.94
- Average True Range (ATR)
- IFRX 0.21
- FCNCP 0.30
- MACD
- IFRX -0.04
- FCNCP -0.05
- Stochastic Oscillator
- IFRX 25.50
- FCNCP 49.38
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About FCNCP First Citizens BancShares Inc.
First Citizens BancShares Inc is the bank holding company of First Citizens Bank and Trust Company. The company's segments include the General Bank, the Commercial Bank, SVB Commercial, and Rail. The General Bank segment delivers products and services to consumers and businesses through its extensive network of branches and various digital channels. The Commercial Bank segment provides financial services, including lending, leasing, and advisory, to small and mid-market businesses across various industries. The SVB Commercial provides financial services to innovators, investors, and venture firms. The Rail segment provides tailored leasing and financing for railcars and locomotives across North America. It generates the majority of its revenue from the General Banking segment.